Aminolevulinic Acid Hydrochloride in Glioblastoma, IDH-Wildtype: ISRCTN14636207 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
10
Planned enrollment
2027-11-01
Primary-completion proxy
Executive view
ISRCTN14636207 evaluates Aminolevulinic Acid Hydrochloride in Glioblastoma, IDH-Wildtype. The disclosed sponsor is Imperial College Healthcare NHS Trust, the design is Interventional, and the geographic footprint is United Kingdom. The first listed primary endpoint is not reported, assessed over an unreported time frame.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for ISRCTN14636207 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Glioblastoma, IDH-Wildtype landscape. Drug & Asset MCP drug_fetch was queried for Aminolevulinic Acid Hydrochloride, while Company & Deal Intelligence MCP organization_fetch was queried for Imperial College Healthcare NHS Trust.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| ISRCTN14636207 | Aminolevulinic Acid Hydrochloride | Phase 1 / Recruiting | Imperial College Healthcare NHS Trust | United Kingdom | 2027-11-01 | |
| NCT07655869 | Lutetium-177 EBRGD | Early Phase 1 / Recruiting | Beijing Tiantan Hospital | China | Incidence of Dose-Limiting Toxicities (DLTs) Within 6 weeks (42 days) after the first dose (during the first two c… | 2026-12-31 |
| NCT07648823 | [177Lu]Lu-zolbetuximab | Early Phase 1 / Recruiting | Beijing Tiantan Hospital | China | Radiation Dosimetry 30 minutes, 2 hours, 24 hours, 48 hours, 72 hours, and 5-7 days post… | 2027-06-20 |
| NCT07635173 | Temozolomide | Phase 1 / Completed | Sponsor not reported | China | dose-limiting toxicity (DLT) From enrollment to the end of treatment at 4 weeks | 2024-04-22 |
| NCT07604285 | MT-125 | Phase 1/2 / Not yet recruiting | Myosin Therapeutics, Inc. | United States | Dose Limiting Toxicity Measurement Day 1 through 6 weeks of treatment | 2027-03-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
ISRCTN14636207 is a Phase 1, recruiting study with 10 planned participants. Allocation is not reported, masking is not reported, and the intervention model is not reported.
The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: Safety: Safety will be evaluated by patient examination and MRI images during the treatment, immediately post-treatment and on day 1 and week 1 post-treatment. Feasibility: The extent of the sonicated area will be calculated at the end of the procedure in order to evaluate the targeted area. Tumour regression will be determined by contrast enhancement on post-procedural serial contrast-enhanced MR images. Pathological examination and immunohistochemistry of the resected specimen will also be utilized to verify the amount of cell apoptosis and necrosis..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 10 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Glioblastoma, IDH-Wildtype. These records do not establish direct evidence for ISRCTN14636207 unless the registration number matches.
Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma
Phase 1; n=12; AE = Of 20 adverse events, two were grade 3 (transient lymphocytopenia), four grade 2, and fourteen grade 1 ; AE = Of 20 adverse events, two were grade 3 (transient lymphocytopenia), four grade 2, and fourteen grade 1 Source: https://pubmed.ncbi.nlm.nih.gov/42229231/
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide i…
Phase 2; n=624; Median Survival Time (Within Center Group)(Median): Cox Proportional Hazard = 0.95(70% CI, 0.81 - 1.10), P-Value = 0.25; Cox Proportional Hazard = 0.81(70% CI, 0.67 - 0.98), P-Value = 0.11; Median Survival Time (Within Center Group)(Median) = 22.8 months (95% Confidence Interval, 20.0 - 28.6) Source: https://clinicaltrials.gov/ct2/show/results/NCT02179086
A First-in-Human Clinical Trial of Pharmacologic Ascorbate and Ferumoxytol Combined With Concomitant Temozolomide and External Beam Radiation Therapy for Newly Diagnosed Glioblast…
Phase 1; n=16; Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs) = 2 Dose Limiting Toxicities ; Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs) = 0 Dose Limiting Toxicities Source: https://clinicaltrials.gov/ct2/show/results/NCT04900792
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “Aminolevulinic Acid Hydrochloride.” The report therefore avoids inferring modality, target or global development stage from the name alone.
No exact Company & Deal Intelligence profile was returned for Imperial College Healthcare NHS Trust. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Aminolevulinic Acid Hydrochloride is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: ISRCTN14636207
Protocol source: https://www.isrctn.com/ISRCTN14636207
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Aminolevulinic Acid Hydrochloride in Glioblastoma, IDH-Wildtype is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and 2027-11-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
